Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2814 SAD/MAD in Healthy Subjects
NCT04231513Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2019
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of etalanetug in Alzheimer's disease (AD) (9 cohorts), sponsored by Eisai Co., Ltd. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) up to 169 days, Number of Participants With Clinically Significant Laboratory Values up to 169 days and 2 more. Started Dec 2019; status: completed.
02
Drugs
etalanetug
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04231513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04231513.